FAQ

nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
01220102016

Related topics

Related topics

3 relations

Narrower (1)

APD125

Broader (2)

Phenylurea CompoundsPyrazoles

Related mentions per year

Related mentions per year

1949-2018
19401960198020002020
nelotanserin
Pyrazoles
Phenylurea Compounds
APD125

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
New Therapeutic Strategies for Lewy Body Dementias.
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available… (More)
Is this relevant?
Review
2017
Review
2017
Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the… (More)
  • table 1
Is this relevant?
2016
2016
The Effects of Benzodiazepine and Nonbenzodiazepine Agents, Ramelteon, Low-dose Doxepin, Suvorexant, and Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists on Sleep and Wakefulness
Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the… (More)
  • table 1
  • table 2
  • table 4
  • table 3
  • table 5
Is this relevant?
Review
2011
Review
2011
Serotonin control of sleep-wake behavior.
Based on electrophysiological, neurochemical, genetic and neuropharmacological approaches, it is currently accepted that… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.
5-Hydroxytryptamine (5-HT)(2A) receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2010
2010
Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily… (More)
Is this relevant?